VX-770 for the Treatment of Chronic Bronchitis

Status Withdrawn

Clinical Trial Summary

This research study will test how well a new drug affects bronchiectasis or chronic bronchitis. The new drug, Ivacaftor (KALYDECO), is a drug that has recently been approved by the U.S. Food and Drug Administration (FDA) for patients with a lung disease called Cystic Fibrosis (CF). It has not been approved for use in patients with bronchiectasis or chronic bronchitis.

Clinical Trial Description

The study is an open label study of orally-administered ivacaftor in subjects with chronic bronchitis and/or bronchiectasis. Subjects will be administered the study drug ivacaftor 150 mg twice daily (BID). The study drug is commercially available and will be purchased by the participant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03251911
Study type	Interventional
Source	University of Alabama at Birmingham
Contact
Status	Withdrawn
Phase	Phase 4
Start date	January 1, 2020
Completion date	February 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05533931` - Resistive Breathing Versus Inspiratory Hold Technique in Patients With Chronic Bronchitis	N/A
Completed	`NCT01420445` - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis	Phase 2
Completed	`NCT01071161` - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough	Phase 3
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT00903955` - Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease	N/A
Completed	`NCT00129883` - Adherence to Guidelines for Antibiotic Use in Respiratory Infections at Hospitals	N/A
Recruiting	`NCT05075083` - Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD	Phase 4
Recruiting	`NCT05075057` - Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD	Phase 4
Terminated	`NCT02838108` - The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Completed	`NCT02128529` - Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)	N/A
Withdrawn	`NCT00298402` - Macrophages in Smokers' Lung	N/A
Completed	`NCT00298389` - Macrophage Phagocytosis in COPD
Terminated	`NCT00132951` - KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections	Phase 4
Active, not recruiting	`NCT01969344` - Study of COPD Subgroups and Biomarkers
Completed	`NCT00680056` - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients	Phase 4
Completed	`NCT00106080` - Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)	N/A
Completed	`NCT00042718` - A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.	Phase 3
Completed	`NCT02099799` - The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD	N/A
Completed	`NCT00342030` - Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans	N/A
Withdrawn	`NCT02341183` - Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects	N/A